Identification of an endothelin-converting enzyme-2-specific fluorigenic substrate and development of an in vitro and ex vivo enzymatic assay.
Endothelin-converting enzyme-2 (ECE-2) is a membrane-bound zinc-dependent metalloprotease that shares a high degree of sequence homology with ECE-1, but displays an acidic pH optimum characteristic of maturing enzymes acting late in the secretory pathway. Although ECE-2, like ECE-1, can cleave the big endothelin intermediate to produce the vasoconstrictive endothelin peptide, its true physiological function remains to be elucidated, a task that is hampered by the lack of specific tools to study and discriminate ECE-2 from ECE-1, i.e. specific substrates and/or specific inhibitors. To fill this gap, we searched for novel ECE-specific peptide substrates. To this end, peptides derived from the big endothelin intermediate were tested using ECE-1 and ECE-2, leading to the identification of an ECE-1-specific substrate. Moreover, screening of our proprietary fluorigenic peptide Fluofast® libraries using ECE-1 and ECE-2 allowed the identification of Ac-SKG-Pya-F-W-Nop-GGK-NH(2) (PL405), as a specific and high affinity ECE-2 substrate. Indeed, ECE-2 cleaved PL405 at the Pya-F amide bond with a specificity constant (k(cat)/K(m)) of 8.1 ± 0.9 × 10(3) M(-1) s(-1). Using this novel substrate, we also characterized the first potent (K(i) = 7.7 ± 0.3 nM) and relatively selective ECE-2 inhibitor and developed a quantitative fluorigenic ECE-2 assay. The assay was used to study the ex vivo ECE-2 activity in wild type and ECE-2 knock-out tissues and was found to truly reflect ECE-2 expression patterns. The PL405 assay is thus the first tool to study ECE-2 inhibition using high throughput screening or for ex vivo ECE-2 quantification.
Ouimet
Tanja
T
Pharmaleads, Paris BioPark, 75013 Paris, France.
Orng
Sou-Vinh
SV
Poras
Hervé
H
Gagnidze
Khatuna
K
Devi
Lakshmi A
LA
Fournié-Zaluski
Marie-Claude
MC
Roques
Bernard P
BP
D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000008:administration & dosage / Q000096:biosynthesis* / Q000737:chemistry* / Q000235:genetics; D000072396:Endothelin-Converting Enzymes; D016232:Endothelins / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D057075:Enzyme Assays / Q000379:methods*; D004791:Enzyme Inhibitors / Q000737:chemistry; D005456:Fluorescent Dyes / Q000737:chemistry*; D015971:Gene Expression Regulation, Enzymologic / Q000502:physiology*; D006801:Humans; D008666:Metalloendopeptidases / Q000008:administration & dosage / Q000096:biosynthesis* / Q000737:chemistry* / Q000235:genetics; D051379:Mice; D009928:Organ Specificity; D019151:Peptide Library; D010455:Peptides / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism; D013379:Substrate Specificity
D016232:Endothelins; D004791:Enzyme Inhibitors; D005456:Fluorescent Dyes; D019151:Peptide Library; D010455:Peptides; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; C000606923:ECE1 protein, human; C000606924:ECE2 protein, human; C000606925:Ece1 protein, mouse; C000606926:Ece2 protein, mouse; D000072396:Endothelin-Converting Enzymes
Biochemistry. 1989 Feb 21;28(4):1493-7
2719912
Science. 2001 May 25;292(5521):1550-2
11375493
J Biol Chem. 2006 Oct 13;281(41):30471-8
16912050
Biochem Cell Biol. 1987 Apr;65(4):398-404
3300709
Mol Psychiatry. 2004 Dec;9(12):1122-8, 1059
15340356
Biochem Biophys Res Commun. 2000 May 19;271(3):565-70
10814502
Biochim Biophys Acta. 1970 Apr 22;206(1):136-42
4315054
J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S22-5
11078325
Exp Cell Res. 2007 Feb 1;313(3):450-61
17188679
J Biol Chem. 1988 Mar 15;263(8):4033-40
2894375
Genes Brain Behav. 2008 Jun;7(4):418-26
21450041
Pharmacol Rev. 1993 Mar;45(1):87-146
8475170
Cell. 1994 Aug 12;78(3):473-85
8062389
Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6353-7
1712490
Arch Biochem Biophys. 1998 Nov 15;359(2):258-68
9808768
Am J Pathol. 2009 Jul;175(1):262-70
19541930
J Biol Chem. 1993 Dec 15;268(35):26759-66
8253812
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4072-6
8171037
J Biol Chem. 1999 Nov 5;274(45):32469-77
10542292
J Biol Chem. 1999 Feb 12;274(7):4053-8
9933597
J Biol Chem. 1995 Jun 23;270(25):15262-8
7797512
Anal Biochem. 2000 Nov 1;286(1):112-8
11038281
Neuron. 2001 Oct 25;32(2):177-80
11683988
Biochem J. 2000 Apr 15;347(Pt 2):419-29
10749671
Brain Res Mol Brain Res. 1999 Feb 5;64(2):211-21
9931490
J Biol Chem. 2003 Apr 25;278(17):14704-11
12560336
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4345-50
10759559
J Mol Biol. 2009 Jan 9;385(1):178-87
18992253
Biochem Soc Trans. 1993 Aug;21 ( Pt 3)(3):678-85
8224489
J Med Chem. 2008 Jun 26;51(12):3378-87
18507370
J Biol Chem. 2003 Jan 24;278(4):2081-4
12464614
Genomics. 1996 Aug 15;36(1):22-8
8812412
Biochem J. 2002 May 1;363(Pt 3):697-705
11964170
J Med Chem. 2002 Mar 28;45(7):1477-86
11906289
J Neurosci. 1989 Dec;9(12):4439-55
2593007
J Clin Invest. 2000 May;105(10):1373-82
10811845
Nature. 1980 Nov 20;288(5788):286-8
7001254
Biochem J. 2001 Jun 15;356(Pt 3):813-9
11389689
Am J Hypertens. 2005 Dec;18(12 Pt 1):1606-13
16364833
Bioorg Med Chem Lett. 2002 Aug 5;12(15):2001-5
12113828
Acta Crystallogr D Biol Crystallogr. 2004 Feb;60(Pt 2):392-6
14747736
Trends Pharmacol Sci. 2000 Dec;21(12):475-83
11121837